YO-2 treatment suppresses the infiltration of inflammatory cells into spleen, liver, and BM of CpG/DG-injected mice. (A) Absolute numbers of CCR2⁺ cells in spleen derived from untreated and CpG/DG-injected mice after treatment with PBS or YO-2 at day 7 (n = 5-7 per group). (B) Absolute numbers of CD3⁺, B220⁺, CD11b⁺, and CD11c⁺ cells in spleens of untreated and CpG/DG-injected mice following treatment with PBS or YO-2 as determined at day 7 (n = 5-7 per group). (C) Absolute numbers of these 4 fractions of CD11b⁺ cells in the spleen of untreated mice and CpG/DG-injected mice treated with PBS or YO-2 at day 7 (n = 5-7 per group). (1) CD11b⁺CD11c⁺ (myeloid dendritic cell), (2) CD11b⁺F4/80⁺ (macrophage), (3) CD11b⁺Ly6g^highLy6c^int (neutrophil), (4) CD11b⁺Ly6g^lowLy6c^high (inflammatory monocyte). (D) Representative images of the immunostaining of CD11b and F4/80 of liver sections derived from untreated and CpG/DG-injected mice treated with PBS or YO-2 at day 4 (left panels; bars represent 200 μm). Right panel, the quantification of indicated positive cells per HPF in different treatment groups (n = 5 per group). (E) Representative images of the immunostaining of F4/80 of BM sections of untreated mice and CpG/DG-injected mice treated with PBS or YO-2 at day 4. Scale bars = 200 μm. Black lines indicate F4/80⁺ cells. Right panel, The quantification of F4/80⁺ cells per HPF of tissue sections (n = 5 per group). Data represent mean ± SEM. *P < .05, **P < .01, ***P < .001, using 1-way ANOVA with the Tukey posttest or the unpaired, 2-tailed Student t test for significance.